Core Viewpoint - The company is committed to a "device + AI" strategy and has not yet ventured into the brain-computer interface field [1] Group 1 - The company has stated its focus on exploring AI in the medical equipment sector [1] - Detailed information regarding the company's activities in the AI medical equipment field can be found in its annual report disclosed on the Giant Tide Information Network [1]

Core Viewpoint - The stock of Kaili Medical (300633) has shown a decline in price and significant changes in financial performance, indicating potential investment considerations and market reactions [1][2]. Financial Performance - For the first three quarters of 2025, Kaili Medical reported a main revenue of 1.459 billion yuan, an increase of 4.37% year-on-year [2]. - The net profit attributable to shareholders was 33.51 million yuan, a decrease of 69.25% year-on-year [2]. - The net profit after deducting non-recurring items was 23.99 million yuan, down 72.14% year-on-year [2]. - In Q3 2025, the company achieved a single-quarter main revenue of 495 million yuan, up 28.42% year-on-year [2]. - The single-quarter net profit attributable to shareholders was -13.52 million yuan, an increase of 78.05% year-on-year [2]. - The single-quarter net profit after deducting non-recurring items was -15.89 million yuan, an increase of 76.92% year-on-year [2]. - The company's debt ratio stands at 24.22%, with investment income of 2.08 million yuan and financial expenses of -38.30 million yuan [2]. - The gross profit margin is reported at 60.36% [2]. Market Activity - As of January 19, 2026, the stock closed at 28.5 yuan, down 1.08%, with a turnover rate of 0.8% [1]. - The trading volume was 34,400 hands, with a total transaction amount of 99.12 million yuan [1]. - On January 19, the net outflow of main funds was 5.936 million yuan, accounting for 5.99% of the total transaction amount [1]. - Retail investors saw a net inflow of 4.33 million yuan, representing 4.37% of the total transaction amount [1]. Analyst Ratings - In the last 90 days, 10 institutions have provided ratings for Kaili Medical, with 8 buy ratings and 2 hold ratings [2]. - The average target price set by institutions over the past 90 days is 3.971 billion yuan [2].

Group 1 - The core viewpoint of the news is that Kaili Medical has experienced a decline in stock price and financing activities, indicating potential challenges in its financial performance and market perception [1][2]. Group 2 - On January 16, Kaili Medical's stock fell by 3.13%, with a trading volume of 154 million yuan. The net financing buy was -9.43 million yuan, with a total financing balance of 138 million yuan, which is 1.11% of its market capitalization [1]. - As of September 30, 2025, Kaili Medical reported a revenue of 1.459 billion yuan, a year-on-year increase of 4.37%, while the net profit attributable to shareholders decreased by 69.25% to 33.51 million yuan [2]. - The company has distributed a total of 381 million yuan in dividends since its A-share listing, with 258 million yuan distributed in the last three years [3]. Group 3 - As of September 30, 2025, the number of shareholders increased by 12.75% to 16,100, while the average circulating shares per person decreased by 11.31% to 26,824 shares [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited increased its holdings by 1.7193 million shares to 7.4004 million shares, while Huabao Zhongzheng Medical ETF reduced its holdings by 1.0673 million shares to 6.1194 million shares [3].

Core Viewpoint - The stock of Kaili Medical (300633) has experienced a decline, with significant changes in its financial performance and capital flow, indicating potential investment opportunities and risks in the medical equipment sector [1][2]. Financial Performance - For the first three quarters of 2025, Kaili Medical reported a main revenue of 1.459 billion yuan, an increase of 4.37% year-on-year [2]. - The net profit attributable to shareholders was 33.51 million yuan, a decrease of 69.25% year-on-year [2]. - The net profit after deducting non-recurring items was 23.99 million yuan, down 72.14% year-on-year [2]. - In Q3 2025, the company achieved a single-quarter main revenue of 495 million yuan, up 28.42% year-on-year [2]. - The single-quarter net profit attributable to shareholders was -13.52 million yuan, an increase of 78.05% year-on-year [2]. - The single-quarter net profit after deducting non-recurring items was -15.89 million yuan, an increase of 76.92% year-on-year [2]. - The company's debt ratio stands at 24.22%, with investment income of 2.08 million yuan and financial expenses of -38.30 million yuan [2]. - The gross profit margin is reported at 60.36% [2]. Stock Performance and Capital Flow - As of January 16, 2026, Kaili Medical's stock closed at 28.81 yuan, down 3.13%, with a turnover rate of 1.22% and a trading volume of 52,900 lots, amounting to a total transaction value of 154 million yuan [1]. - On January 16, the net outflow of main funds was 27.89 million yuan, accounting for 18.13% of the total transaction value [1]. - The net inflow of retail funds was 13.13 million yuan, representing 8.54% of the total transaction value [1]. - Over the past 90 days, 10 institutions have provided ratings for the stock, with 8 buy ratings and 2 hold ratings [2]. - The average target price set by institutions over the past 90 days is 39.71 yuan [2].

开立医疗2025年三季报显示，前三季度公司主营收入14.59亿元，同比上升4.37%；归母净利润3351.11 万元，同比下降69.25%；扣非净利润2399.1万元，同比下降72.14%；其中2025年第三季度，公司单季度 主营收入4.95亿元，同比上升28.42%；单季度归母净利润-1351.92万元，同比上升78.05%；单季度扣非 净利润-1588.57万元，同比上升76.92%；负债率24.22%，投资收益207.82万元，财务费用-3830.36万 元，毛利率60.36%。开立医疗（300633）主营业务：医疗诊断及治疗设备的自主研发、生产与销售。 该股最近90天内共有10家机构给出评级，买入评级8家，增持评级2家；过去90天内机构目标均价为 39.71。 资金流向名词解释：指通过价格变化反推资金流向。股价处于上升状态时主动性买单形成的成交额是推 动股价上涨的力量，这部分成交额被定义为资金流入，股价处于下跌状态时主动性卖单产生的的成交额 是推动股价下跌的力量，这部分成交额被定义为资金流出。当天两者的差额即是当天两种力量相抵之后 剩下的推动股价上升的净力。通过逐笔交易单成交金额计算主力资金流向、游资 ...

Core Viewpoint - The medical equipment procurement scale is expected to grow rapidly year-on-year due to the implementation of the 2025 equipment renewal policy, with a significant increase in demand for high-end medical devices [1][2][3] Group 1: Equipment Procurement Trends - In December 2025, the procurement scale for new medical devices showed a decline in MR by 11.8%, CT by 7.3%, DR by 3.9%, and ultrasound by 1.3%, while endoscopes increased by 1.4% and surgical robots decreased by 23.9% [1][2] - Cumulatively for the year 2025, the procurement scale for MR increased by 31.4%, CT by 53.2%, DR by 53.2%, ultrasound by 42.3%, endoscopes by 16.3%, and surgical robots by 21.9% [2] Group 2: Company Performance - In December 2025, the performance of specific companies showed that Union Medical's MR declined by 17.4%, while its CT increased by 17.4%. Mindray's ultrasound grew by 13.8%, and KAILI's ultrasound decreased by 13.5%. KAILI's endoscope increased by 61.1%, and Aohua's endoscope grew by 9.4% [2] - For the entire year of 2025, Union Medical's MR grew by 15.6%, CT by 47.7%, Mindray's ultrasound by 56.3%, KAILI's ultrasound by 69.7%, KAILI's endoscope by 85.0%, and Aohua's endoscope by 24.4% [2] Group 3: Policy Impact - The 2024 policy aims to increase medical equipment investment by over 25% compared to 2023 by 2027, enhancing the configuration of high-end equipment to levels seen in middle-income countries [3] - The implementation of the equipment renewal policy is expected to significantly boost procurement levels across various medical institutions, leading to a recovery in the domestic market and a turning point for equipment companies [3]

证券之星消息，截至2026年1月13日收盘，开立医疗(300633)报收于29.3元，下跌0.51%，换手率 1.34%，成交量5.82万手，成交额1.72亿元。 1月13日的资金流向数据方面，主力资金净流入19.59万元，占总成交额0.11%，游资资金净流入202.37 万元，占总成交额1.18%，散户资金净流出221.96万元，占总成交额1.29%。 近5日资金流向一览见下表： 该股主要指标及行业内排名如下： 开立医疗2025年三季报显示，前三季度公司主营收入14.59亿元，同比上升4.37%；归母净利润3351.11 万元，同比下降69.25%；扣非净利润2399.1万元，同比下降72.14%；其中2025年第三季度，公司单季度 主营收入4.95亿元，同比上升28.42%；单季度归母净利润-1351.92万元，同比上升78.05%；单季度扣非 净利润-1588.57万元，同比上升76.92%；负债率24.22%，投资收益207.82万元，财务费用-3830.36万 元，毛利率60.36%。开立医疗（300633）主营业务：医疗诊断及治疗设备的自主研发、生产与销售。 该股最近90天内共有10家机构给出评级 ...

证券日报网讯1月13日，开立医疗（300633）在互动平台回答投资者提问时表示，随着国内终端招标的 持续恢复，公司2025年的营收呈现逐季好转趋势。 ...

证券之星消息，截至2026年1月12日收盘，开立医疗(300633)报收于29.45元，上涨1.66%，换手率 1.25%，成交量5.4万手，成交额1.58亿元。 | | | | | 日期 收盘价 涨跌幅 主力净流入 主力净占比 游资净点比 游资净占比 散户净占比 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 2026-01-12 | 29.45 | 1.66% | -1509.90万 | -9.54% | -161.49万 | -1.02% | 1671.39万 | - 10.56% | | 2026-01-09 | 28.97 | 0.42% | -549.55万 | -3.89% | 53.42万 | 0.38% | 496.13万 | 3.52% | | 2026-01-08 | 28.85 | 0.59% | -1523.37万 | -8.59% | 2890.71万 | 16.29% | -1367.34万 | -7.71% | | 2026-01-07 | 28.68 | 3.91% | -1635.01万 ...

证券之星消息，截至2026年1月8日收盘，开立医疗(300633)报收于28.85元，上涨0.59%，换手率 1.42%，成交量6.14万手，成交额1.77亿元。 1月8日的资金流向数据方面，主力资金净流出1523.37万元，占总成交额8.59%，游资资金净流入 2890.71万元，占总成交额16.29%，散户资金净流出1367.34万元，占总成交额7.71%。 近5日资金流向一览见下表： 该股主要指标及行业内排名如下： 开立医疗2025年三季报显示，前三季度公司主营收入14.59亿元，同比上升4.37%；归母净利润3351.11 万元，同比下降69.25%；扣非净利润2399.1万元，同比下降72.14%；其中2025年第三季度，公司单季度 主营收入4.95亿元，同比上升28.42%；单季度归母净利润-1351.92万元，同比上升78.05%；单季度扣非 净利润-1588.57万元，同比上升76.92%；负债率24.22%，投资收益207.82万元，财务费用-3830.36万 元，毛利率60.36%。开立医疗（300633）主营业务：医疗诊断及治疗设备的自主研发、生产与销售。 该股最近90天内共有10家机构 ...